Bind Biosciences Inc. of Cambridge, Mass., has received a three-year, $2 million award from the National Institute of Standards and Technology of Gaithersburg, Md. The grant will fund the continuing development of a platform for the high-throughput formulation and selection of targeted nanoparticles. The company hopes to use the device to create a class of therapeutics based on optimally engineered particles.